Under the agreement, Aureus will provide AurSCOPE knowledge databases and continue to update existing databases for Sanofi-Aventis’ R&D division. These databases are expected to give Sanofi-Aventis researchers access to information on major therapeutic targets.
The therapeutic targets include G protein-coupled receptor, protein receptors, nuclear receptors, kinase inhibitors, ion channels, as well as information relative to drug safety including data on absorption, distribution, metabolism, and excretion.
The new agreement reinforces the relationship between Aureus Pharma and Sanofi-Aventis, which has been in existence for the last seven years. It also secures additional revenues for Aureus over the next three years.
Jason Theodosiou, CEO of Aureus Pharma, said: Sanofi-aventis’ decision to extend the partnership for an additional three year period, as well as to acquire new knowledge bases, confirms the fact that Aureus´ products are meeting the needs of the world´s leading pharmaceutical companies.